19693-76-6

Basic information

• Product Name: 1,3-Dioxolane, 2-(4-ethenylphenyl)-
• Synonyms: 2-(p-vinylphenyl)-1,3-dioxolane;4-vinylbenzaldehyde ethylene acetal;2-(4-vinylphenyl)-1,3-dioxolane;1,3-Dioxolane,2-(4-ethenylphenyl)
• CAS NO: 19693-76-6
• Molecular Formula: C11H12O2
• Molecular Weight: 176.215
• Mol File: 19693-76-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 105 °C
• Density: 1.094±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1,3-Dioxolane, 2-(4-ethenylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxolane, 2-(4-ethenylphenyl)-(19693-76-6)
• EPA Substance Registry System: 1,3-Dioxolane, 2-(4-ethenylphenyl)-(19693-76-6)

Safety Data

• Hazardous Substances Data: 19693-76-6(Hazardous Substances Data)

Upstream product

• 76084-77-0 2-p-(β-bromoethylphenyl)-1,3-dioxolane 
• 1791-26-0 4-vinyl-benzaldehyde 
• 107-07-3 2-chloro-ethanol 
• 103-63-9 1-phenyl-2-bromoethane 
• 7617-70-1 4-(2-Bromoethyl)benzaldehyde 
• 108-05-4 vinyl acetate 
• 10602-01-4 p-bromobenzaldehyde 1,3-dioxolane 
• 107-21-1 ethylene glycol 
• 623-27-8 terephthalaldehyde, 

Downstream Products

• 43153-07-7 2-(4-formylphenyl)propanoic acid 
• 163164-47-4 4-mono(2-hydroxyethyl)benzaldehyde 
• 1791-26-0 4-vinyl-benzaldehyde 

Relevant articles and documents

Nickel-Catalyzed Reductive Cross-Coupling of Aryl Bromides with Vinyl Acetate in Dimethyl Isosorbide as a Sustainable Solvent

A nickel-catalyzed reductive cross-coupling has been achieved using (hetero)aryl bromides and vinyl acetate as the coupling partners. This mild, applicable method provides a reliable access to a variety of vinyl arenes, heteroarenes, and benzoheterocycles, which should expand the chemical space of precursors to fine chemicals and polymers. Importantly, a sustainable solvent, dimethyl isosorbide, is used, making this protocol more attractive from the point of view of green chemistry.

Detection of amines with extended distyrylbenzenes by strip assays

We herein describe the synthesis and property evaluation of three novel aldehyde-substituted pentameric phenylenevinylenes carrying branched oligo(ethylene glycol) (swallowtail, Sw) substituents. The targets were synthesized by a combination of Heck coupling and Wittig or Horner reactions of suitable precursor modules. If the pentameric phenylenevinylene carries only two of these Sw substituents, it is no longer water-soluble. When six of the Sw substituents are attached, regardless of their position, the pentameric phenylenevinylenes are well water-soluble. The dialdehydes were investigated with respect to their amine-sensing capabilities both in water as well as in the solid state, sprayed onto thin layer chromatography (TLC) plates (alox, silica gel, reversed phase silica gel). The recognition of amine vapors using the sprayed-on phenylenevinylene dialdehydes is superb and allows the identification of different amines on regular silica TLC plates via color changes, analyzed by a statistical tool, the multivariate analysis of variance (MANOVA) protocol.

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.